1. A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy.
- Author
-
Hirayama M, Hatou S, Nomura M, Hokama R, Hirayama OI, Inagaki E, Aso K, Sayano T, Dohi H, Hanatani T, Takasu N, Okano H, Negishi K, and Shimmura S
- Subjects
- Humans, Male, Female, Middle Aged, Endothelial Cells metabolism, Endothelium, Corneal pathology, Aged, Corneal Transplantation methods, Corneal Diseases pathology, Corneal Diseases surgery, Corneal Diseases therapy, Transplantation, Homologous methods, Visual Acuity, Adult, Induced Pluripotent Stem Cells metabolism
- Abstract
A first-in-human investigator-initiated clinical study of a corneal endothelial cell substitute (CLS001) derived from a clinical-grade induced pluripotent stem cell (iPSC) line shows improvement of visual acuity and corneal stromal edema, with no adverse events for up to 1 year after surgery for the treatment of bullous keratopathy. While preclinical tests, including multiple whole-genome analysis and tumorigenicity tests adhering to the Food and Drug Administration (FDA) draft guidelines, are negative, an additional whole-genome analysis conducted on transplanted CLS001 cells reveals a de novo in-frame deletion of exon22 in the EP300 gene. No adverse events related to the mutation are observed. Our study demonstrates the feasibility of using iPSC-derived cells to replace donor transplant for bullous keratopathy, while shedding light on risk management of gene mutation in cell products. Further follow-up is required for long-term analysis of clinical safety and efficacy., Competing Interests: Declaration of interests S.S. and S.H. have a patent on CLS001 differentiation protocol., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF